111 results about "Calcitonin" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The invention discloses an abdominal aortic aneurysm progress prediction method and system based on cross-modal knowledge distillation. The method comprises the following steps: collecting blood of a target object; the method comprises the following steps: detecting the concentration of blood protein fingerprint markers of blood of a target object, wherein the blood protein fingerprint markers comprise matrix metalloproteinase-12, calcitonin-related polypeptide-alpha, uromodulin, nerve injury induction protein-1, glycosylated hemoglobin A1c and fibroblast growth factor-9; carrying out abdominal aortic aneurysm risk calculation by calling Student-net of cross-modal knowledge distillation based on the blood protein fingerprint marker concentration; wherein the input of the Teaser-net of the cross-modal knowledge distillation comprises a CTA image feature and a pathological section feature, and a category probability vector output by the Student-net is aligned with a category probability vector output by the Teaser-net; and outputting the risk level of the abdominal aortic aneurysm and the probability of occurrence / progress / rupture of the abdominal aortic aneurysm in the preset year. And the development of the aortic aneurysm disease is accurately predicted.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The inventors discovered that calcitonin gene-related peptide (CGRP) inhibitors reduce pain caused by bone fracture without impeding healing of the fracture. Accordingly, disclosed herein are methods for treating pain in a subject that has sustained a bone fracture, and the methods comprise administering a therapeutically effective amount of a CGRP inhibitor to the subject.

The invention relates to a sepsis detection system which evaluates the sepsis risk of a patient in real time by integrating clinical signs, various physiological parameters, laboratory detection data and biomarkers and utilizing an intelligent algorithm. The system comprises a data acquisition module, a data transmission module, a data processing module, a user display module and an alarm module. The data acquisition module monitors physiological parameters such as consciousness, body temperature, heart rate, respiratory rate, finger pulse oxygen saturation, invasive blood pressure, urine volume and skin piebald in real time, and biomarker data such as leukocyte count, neutrophile granulocyte, neutrophile granulocyte number, C-reactive protein, procalcitonin and interleukin-6 are obtained through blood detection. And the data processing module performs sepsis risk assessment by integrating the biomarkers and the physiological parameters in combination with a machine learning model, and outputs a risk level. The user display module displays the evaluation result in real time and provides treatment suggestions, and the alarm module triggers an alarm under the high-risk condition to ensure timely intervention.

The present invention relates to a process for preparing the compound of Formula I in the form of a base or a salt thereof, and its use as an intermediate for the preparation of calcitonin gene- related peptide (CGRP) receptor antagonist active pharmaceutical ingredients, in particular zavegepant, where the compound of Formula I is the following: (I)

Nausea and vomiting are unpleasant events caused by a variety of triggering factors. Wherein medicines often cause nausea and vomiting. An anti-tumor chemotherapeutic agent is one of the most emetic drugs, and often causes chemotherapy-induced nausea and vomiting (CINV). The latter seriously impairs the therapeutic effect and the quality of life of the patient. It is of great interest in determining agents capable of preventing and combating drug-induced nausea and vomiting, including CINV. A calcitonin gene-related peptide (CGRP) is a neuropeptide having various effects in a human body. However, neuropeptide effects in the brain are still to be clarified. CGRP receptor antagonists (named as gezepam) have been recently approved for use in the treatment of migraine. The use of gezepams for the direct treatment of nausea and vomiting, including CINV, is described.

The application discloses a kind of light illumination methods for laying hens in later egg production stage.The method comprises: in the breeding process of laying hens in later egg production stage, using light source to emit blue light illumination or blue light and white light illumination to irradiate laying hens, so that the illumination can improve eggshell quality.The method of the application can up-regulate the expression of CaBP-D28k gene in eggshell gland of laying hens in later production stage, improve the ability of eggshell calcium deposition, regulate the secretion of parathyroid hormone PTH, calcitonin CT and other hormones, maintain the balance of blood calcium and blood phosphorus, and effectively improve the strength, thickness and weight of eggshell, so as to improve the eggshell quality of eggs produced by laying hens.The application can improve the calcium and phosphorus absorption capacity of laying hens, maintain the balance of calcium and phosphorus metabolism, and has low energy consumption, green energy-saving and environment-friendly advantages.

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and / or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, so can be used to treat diabetes, obesity and / or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

The invention relates to a calcitonin luminescence detection kit and a detection method and application thereof. Specifically, the invention provides the high-sensitivity calcitonin luminescence detection kit, the high-sensitivity calcitonin luminescence detection kit comprises a first reagent and a second reagent, and the first reagent comprises magnetic beads connected with first protein; the second reagent comprises alkaline phosphatase connected with the second protein. The kit improves the detection accuracy and the sample coincidence rate.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The application provides a photochemical chemiluminescence detection reagent and a preparation method thereof, and a procalcitonin detection method. The photochemical chemiluminescence detection reagent comprises acceptor microspheres and donor microspheres; wherein the acceptor microspheres are carboxyl-modified acceptor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody; and the donor microspheres are carboxyl-modified donor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody. The photochemical chemiluminescence detection reagent has higher stability in various environments, can more accurately combine with target molecules, realizes more efficient detection and recognition, and enables the microspheres to more accurately capture and fix the target molecules, so as to perform subsequent luminescence reaction. The detection method has high sensitivity and a wide range, can be used as a detection reagent for diagnosing and identifying infectious diseases of individuals, and has application value.

The present invention discloses an anti-procalcitonin antibody or a reagent and kit for detecting procalcitonin, relating to the field of antibodies. The anti-procalcitonin antibody disclosed in the present invention comprises a heavy chain complementary determining region and a light chain complementary determining region. The antibody provides an important source of raw materials for the detection of procalcitonin and has good affinity or activity.

Methods of systemically treating neuropathic pain in a spinal cord injured patient by administering a calcitonin gene-related peptide (CGRP) inhibitor are provided. In some variations, pain-producing tissues correlated with sympathetically mediated central neuropathic pain in spinal cord injured (SCI) patients, were acquired.

The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The invention provides a conjugate comprising a peptide that binds to the Calcitonin Gene-Related Peptide Receptor that is linked to a therapeutic or a detectable radionuclide. The conjugates are useful for imaging the Calcitonin Gene-Related Peptide Receptor and for treating diseases wherein the activity of the Calcitonin Gene-Related Peptide Receptor is implicated.

According to this invention, there is provided an automated sample preparation system implemented within a disposable cartridge. The system utilizes finger prick blood or venous blood as an input sample and performs various sample processing steps, including fluidic metering, fluidic routing, and reagent storage with an integrated biosensor. The architecture, of this system, enables efficient and accurate testing of blood parameters, hematology parameters such as CBC, CD4-T cells count, but not limited to, Complete Blood Cell Count (CBC) and measurement of biomarkers such as Troponin, IL-6, Procalcitonin, but not limited to, CRP, Procalcitonin, and IL-6 through ELISA and is flexible to implement other electrochemistry techniques.

Peptides that exhibit amylin and calcitonin receptor agonist activity (DACRAs) are provided as well as prodrug derivatives thereof. Analogs having enhanced agonist selectivity for the calcitonin receptor relative to amylin are also provided as well as conjugates of the DACRA peptides with incretin peptides. Pharmaceutical compositions comprising such peptide analogs and therapeutic methods of using such peptide analogs are also provided.

This invention relates to the field of biomedical data processing technology, specifically to a stratification system for sepsis-related secondary invasive fungal infections based on laboratory data. The invention obtains the degree of static intestinal baseline damage by considering serum lactate concentrations at different historical testing times, temporal characteristics, and a preset maximum backtracking period; it obtains the cumulative dosage of antimicrobial drugs and the hourly cumulative distribution value of drug use based on the drug dosage distribution at different medication times within a neighborhood of the real-time trigger time; it obtains the overall degree of inflammation reduction and the hourly cumulative distribution value of inflammation regression based on the procalcitonin concentration distribution at testing times within a neighborhood; and it further obtains the net drug-induced intervention level. Based on the degree of static intestinal baseline damage and the net drug-induced intervention level, the fungal infection characteristics are stratified. This invention, by considering non-drug-induced interference, accurately obtains the comprehensive risk level of fungal infection, improving the effectiveness of fungal infection stratification.

The invention relates to an electrochemiluminescence sensor based on an intelligent controlled release-interface capture-self-enhancement mechanism and application of the electrochemiluminescence sensor in procalcitonin detection, and belongs to the technical field of electrochemiluminescence detection. Controllable release of signal molecules is achieved by packaging terpyridyl ruthenium through ZIF-8, meanwhile, a DNA layer rich in guanine is modified on an electrode interface, and the layer can serve as a nano trap to efficiently capture the signal molecules and can also serve as a co-reactant to achieve signal amplification. A DNA strand displacement reaction is utilized to regulate and control a target response release process, and detection is realized according to a quantitative relationship between the concentration of procalcitonin and an electrochemical luminescence signal. A labeling recovery method verifies that the recovery rate of the sensor in a human serum sample reaches 100.6-103.6%, good accuracy and precision are shown, and a reliable platform is provided for clinical detection of inflammatory markers.

Disclosed herein is a 4-phenyl-lH-pyrazolo[3,4-b]pyridine-5- carboxamide derivative of formula (I) as amylin and / or calcitonin receptor agonists for the treatment of type 2 diabetes, obesity or overweight.

The invention provides a conjugate comprising a peptide that binds to the Calcitonin Gene-Related Peptide Receptor that is linked to a therapeutic or a detectable radionuclide. The conjugates are useful for imaging the Calcitonin Gene-Related Peptide Receptor and for treating diseases wherein the activity of the Calcitonin Gene-Related Peptide Receptor is implicated.

To provide a biomarker for determining the severity and / or activity of atopic dermatitis.SOLUTION: Disclosed is a biomarker comprising at least one selected from the group consisting of S100A6, S100A8, Lipocapin-2, Fibrinogen, Calcitonin, VWF, Cardiotrophin-1, CystatinA, FGF-18, and Ubiquitin + 1.SELECTED DRAWING: None

Disclosed herein are methods for subtyping patients with a respiratory infection (e.g., community acquired pneuomonia or severe acute respiratory infection) to identify likely responders to corticosteroid therapy. The methods involve analyzing values of a plurality of biomarkers, examples of which include a first biomarker selected from procalcitonin, IL-6, and TREM-1, and a second biomarker selected from Pentraxin-3, MIP-3α, IL-1ra, IL-8, and NGAL. The methods enable personalized treatment decisions for patients with respiratory infections, potentially improving patient outcomes by targeting corticosteroid therapy to those most likely to benefit while avoiding harm to non-responders.